ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
Dow Jones
39.069,59
0,01%
Euro vs US Dollar
1,0848
0,00%
Bitcoin
68.701,65
-0,82%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Bolt Biotherapeutics Inc (BOLT)

  7. Bolt Biotherapeutics Inc (BOLT) News

BOLT

Bolt Biotherapeutics (BOLT)

Bolt Biotherapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BOLT
DatumZeitQuelleÜberschriftSymbolFirma
20/05/202419h22Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:BOLTBolt Biotherapeutics Inc
15/05/202423h43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
14/05/202422h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
14/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
14/05/202422h05GlobeNewswire Inc.Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership TeamNASDAQ:BOLTBolt Biotherapeutics Inc
21/03/202421h05GlobeNewswire Inc.Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
06/03/202419h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
06/03/202419h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
27/02/202413h00GlobeNewswire Inc.Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:BOLTBolt Biotherapeutics Inc
13/02/202403h41Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:BOLTBolt Biotherapeutics Inc
06/02/202419h09Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
21/12/202313h30GlobeNewswire Inc.Pacira Appoints Frank D. Lee as Chief Executive OfficerNASDAQ:BOLTBolt Biotherapeutics Inc
13/12/202319h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
05/12/202313h00GlobeNewswire Inc.Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®NASDAQ:BOLTBolt Biotherapeutics Inc
09/11/202322h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
09/11/202322h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
09/11/202322h05GlobeNewswire Inc.Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
07/11/202313h00GlobeNewswire Inc.Bolt Biotherapeutics to Present at Stifel 2023 Healthcare ConferenceNASDAQ:BOLTBolt Biotherapeutics Inc
23/10/202316h30GlobeNewswire Inc.Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 CongressNASDAQ:BOLTBolt Biotherapeutics Inc
18/10/202313h00GlobeNewswire Inc.Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual MeetingNASDAQ:BOLTBolt Biotherapeutics Inc
17/10/202313h00GlobeNewswire Inc.Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced CancersNASDAQ:BOLTBolt Biotherapeutics Inc
16/10/202313h00GlobeNewswire Inc.Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023NASDAQ:BOLTBolt Biotherapeutics Inc
28/09/202313h00GlobeNewswire Inc.Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric CancersNASDAQ:BOLTBolt Biotherapeutics Inc
12/09/202314h05GlobeNewswire Inc.Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042NASDAQ:BOLTBolt Biotherapeutics Inc
05/09/202322h15GlobeNewswire Inc.Bolt Biotherapeutics to Participate in September Investor ConferencesNASDAQ:BOLTBolt Biotherapeutics Inc
07/08/202322h10GlobeNewswire Inc.Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
07/08/202322h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
07/08/202322h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
03/08/202313h30GlobeNewswire Inc.Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive CancerNASDAQ:BOLTBolt Biotherapeutics Inc
31/07/202323h27GlobeNewswire Inc.Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023NASDAQ:BOLTBolt Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BOLT

Kürzlich von Ihnen besucht

BIT
UV8CHH
UniCredit Bank
BIT
I06561
Banca Imi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten